Darusentan: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>David E. Volk No edit summary |
||
| Line 1: | Line 1: | ||
{{Chem infobox | |||
|align=right | |||
|image=[[Image:Darusentan.png|center|thumb|350px]] | |||
|width=350px | |||
|molname=darusentan | |||
|synonyms= | |||
|molformula= C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub> | |||
|molmass= 410.41988 | |||
|uses=hypertension | |||
|properties= | |||
|hazards=see side effects & drug interactions | |||
|iupac= (2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic | |||
acid | |||
|casnumber= 171714-84-4 | |||
}} | |||
In [[medicine]], '''darusentan''' is a [[medication]] for treating [[hypertension]] that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet {{doi|10.1016/S0140-6736(09)61500-2}}</ref> | In [[medicine]], '''darusentan''' is a [[medication]] for treating [[hypertension]] that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet {{doi|10.1016/S0140-6736(09)61500-2}}</ref> | ||
Revision as of 08:39, 19 September 2009
|
| |||||||
| darusentan | |||||||
| |||||||
| Uses: | hypertension | ||||||
| Properties: | |||||||
| Hazards: | see side effects & drug interactions | ||||||
| |||||||
In medicine, darusentan is a medication for treating hypertension that is a selective endothelin type A antagonist. It is a vasodilator.[1]
Drug toxicity
Fluid retention is the most common drug toxicity.[1]
References
- ↑ 1.0 1.1 Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet DOI:10.1016/S0140-6736(09)61500-2